New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented124-week Phase I/II zigakibart…